Skip to content

house · Committee report

H. Rept. 118-65

PROTECTING HEALTH CARE FOR ALL PATIENTS ACT OF 2023

2023-05-17

Committees

Associated legislation

Text

Minority Views

[To accompany H.R. 485] The Committee on Energy and Commerce, to whom was referred the bill (H.R. 485) to amend title XI of the Social Security Act to prohibit the use of quality-adjusted life years and similar measures in coverage and payment determinations under Federal health care programs, having considered the same, reports favorably thereon with an amendment and recommends that the bill as amended do pass. CONTENTS Page Purpose and Summary.............................................. 3 Background and Need for Legislation.............................. 3 Committee Action................................................. 3 Committee Votes.................................................. 4 Oversight Findings and Recommendations........................... 7 New Budget Authority, Entitlement Authority, and Tax Expenditures 7 Congressional Budget Office Estimate............................. 7 Federal Mandates Statement....................................... 7 Statement of General Performance Goals and Objectives............ 7 Duplication of Federal Programs.................................. 7 Related Committee and Subcommittee Hearings...................... 7 Committee Cost Estimate.......................................... 7 Earmark, Limited Tax Benefits, and Limited Tariff Benefits....... 8 Advisory Committee Statement..................................... 8 Applicability to Legislative Branch.............................. 8 Section-by-Section Analysis of the Legislation................... 8 Changes in Existing Law Made by the Bill, as Reported............ 8 Minority Views................................................... 138 The amendment is as follows: Strike all after the enacting clause and insert the following: SECTION 1. SHORT TITLE. This Act may be cited as the ``Protecting Health Care for All Patients Act of 2023''. SEC. 2. PROHIBITING THE USE OF QUALITY-ADJUSTED LIFE YEARS AND SIMILAR MEASURES IN COVERAGE AND PAYMENT DETERMINATIONS UNDER FEDERAL HEALTH CARE PROGRAMS. (a) In General.--Section 1182(e) of the Social Security Act (42 U.S.C. 1320e-1(e)) is amended-- (1) by inserting ``or treats extending the life of an elderly, disabled, or terminally ill individual as of lower value than extending the life of an individual who is younger, non-disabled, or not terminally ill'' after ``because of an individual's disability''; (2) by inserting ``described in the preceding sentence'' after ``such a similar measure''; (3) by striking ``The Secretary shall not'' and inserting ``A Federal agency (including the CMI (as described in section 1115A)) or State may not''; (4) by striking ``under title XVIII.'' and inserting the following: ``under any Federal health care program (as defined in section 1128B, except that such term shall include the health program established under chapter 89 of title 5, United States Code).''; and (5) by adding at the end the following new sentence: ``Notwithstanding any other provision of law, a Federal agency (including the CMI) or State may not waive the application of the provisions of this subsection (or the provisions of section 1852(o), section 1860D-12(h), section 1902(a)(88), section 1932(b)(9), or section 2102(e)) under section 1115, section 1115A, or any other demonstration or waiver authority.''. (b) Conforming Amendments.-- (1) Medicaid.-- (A) In general.--Section 1902(a) of the Social Security Act (42 U.S.C. 1396a(a)) is amended-- (i) in paragraph (86), by striking ``and'' at the end; (ii) in paragraph (87)(D), by striking the period and inserting ``; and''; and (iii) by inserting after paragraph (87) the following new paragraph: ``(88) provide for compliance with the requirements of section 1182(e) (relating to prohibiting the use of certain measures in coverage determinations, reimbursement, and incentive programs).''. (B) Managed care organizations.--Section 1932(b) of the Social Security Act (42 U.S.C. 1396u-2(b)) is amended by adding at the end the following new paragraph: ``(9) Prohibition on use of quality-adjusted life years.--The provisions of section 1182(e) shall apply to the utilization of a dollars-per-quality adjusted life year or similar measure (as described in such section) by a medicaid managed care organization under this title (or a prepaid inpatient health plan or prepaid ambulatory health plan, as defined in section 438.2 of title 42, Code of Federal Regulations (or any successor regulation), under a contract with the State) in the same manner as such provisions apply to the utilization of such a year or measure by a State under this title.''. (2) CHIP.--Section 2102 of the Social Security Act (42 U.S.C. 1397bb) is amended by adding at the end the following new subsection: ``(e) Prohibition on the Use of Quality-Adjusted Life Years and Similar Measures.--A State child health plan shall provide for compliance with the requirements of section 1182(e) (relating to prohibiting the use of certain measures in coverage determinations, reimbursement, and incentive programs).''. (3) Medicare advantage.--Section 1852 of the Social Security Act (42 U.S.C. 1395w-22) is amended by adding at the end the following new subsection: ``(o) Prohibition on Use of Quality-adjusted Life Years.--The provisions of section 1182(e) shall apply to the utilization of a dollars-per-quality adjusted life year or similar measure (as described in such section) by an MA plan in the same manner as such provisions apply to the utilization of such a year or measure by the Secretary under this title.''. (4) Medicare part d.--Section 1860D-12 of the Social Security Act (42 U.S.C. 1395w-112) is amended by adding at the end the following new subsection: ``(h) Prohibition on Use of Quality-adjusted Life Years.--The provisions of section 1182(e) shall apply to the utilization of a dollars-per-quality adjusted life year or similar measure (as described in such section) by a prescription drug plan in the same manner as such provisions apply to the utilization of such a year or measure by the Secretary under this title.''. (c) Implementation.--The amendments made by this section shall apply beginning on January 1, 2025.

Purpose and Summary

This bill prohibits all federal health care programs, including the Federal Employees Health Benefits Program, and federally funded state health care programs (e.g., Medicaid) from using prices that are based on quality-adjusted life years or other similar measures to determine relevant thresholds for coverage, reimbursements, or incentive programs.

Background and Need for Legislation

Quality Adjusted Life Years (QALYs) are a cost- effectiveness measurement used by health care payers as a means to determine the value and necessity in paying for a treatment or prescription drug. When using QALYs, payers will assign a relative value to a beneficiary's life and the value gained from offering a particular course of treatment for the individual, relative to the cost of the treatment. While managing costs for treatments remains a priority for everyone, the practice of assigning a particular value to a beneficiary's life and the relative value a treatment would provide has been cited frequently by the disability community as a cause for concern that could lead to an undermining of access to care for people with disabilities if their lives are undervalued and considered not worth receiving care. Because of these concerns, Medicare is already prohibited from using QALYs and other similar, discriminatory measures.\1\ Groups, including the nonpartisan National Council on Disability, however, have called for an extension of Medicare's prohibition on using QALYs and other similar measures to other federal health care programs, like Medicaid, to stop further discrimination.\2\ --------------------------------------------------------------------------- \1\42 USC 1320e-1(e). \2\https://ncd.gov/sites/default/files/ NCD_Quality_Adjusted_Life_Report_508.pdf. --------------------------------------------------------------------------- H.R. 485 would extend Medicare's current prohibition on using QALYs and other similar measures to all federal health care programs, defined as those under 42 U.S.C. 1320a-7b, while also including the definition of the Federal Employees Health Benefits Program.

Committee Action

On February 1, 2023, the Subcommittee on Health held a hearing on H.R. 485. The Subcommittee received testimony from: Kandi Pickard, National Down Syndrome Society Frederick Isasi, Families USA On March 8, 2023, the Subcommittee on Health met in open markup session and forwarded H.R. 485, as amended, to the full Committee by a voice vote. On March 23, 2023, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 485, as amended, favorably reported to the House by a recorded vote of 27 yeas and 20 nays and 1 present.

Committee Votes

The following reflects the record votes taken during the Committee consideration: Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 485 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to prohibit the usage of QALYs and other similar measures in federal health care programs. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 485 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 485: On February 1, 2023, the Subcommittee on Health held a hearing on H.R. 485. The Subcommittee received testimony from: Kandi Pickard, National Down Syndrome Society Frederick Isasi, Families USA Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 485 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides a short title of ``Protecting Health Care for All Patients Act of 2023.'' Section 2. Prohibiting the use of quality-adjusted life years and similar measures in coverage and payment determinations under Federal health care programs Section 2 includes language prohibiting the use of the quality-adjusted life years and similar measures in coverage and payment determinations under federal health care programs. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): SOCIAL SECURITY ACT * * * * * * * TITLE XI--GENERAL PROVISIONS, PEER REVIEW, AND ADMINISTRATIVE SIMPLIFICATION * * * * * * * Part D--Comparative Clinical Effectiveness Research * * * * * * * limitations on certain uses of comparative clinical effectiveness research Sec. 1182. (a) The Secretary may only use evidence and findings from research conducted under section 1181 to make a determination regarding coverage under title XVIII if such use is through an iterative and transparent process which includes public comment and considers the effect on subpopulations. (b) Nothing in section 1181 shall be construed as-- (1) superceding or modifying the coverage of items or services under title XVIII that the Secretary determines are reasonable and necessary under section 1862(l)(1); or (2) authorizing the Secretary to deny coverage of items or services under such title solely on the basis of comparative clinical effectiveness research. (c)(1) The Secretary shall not use evidence or findings from comparative clinical effectiveness research conducted under section 1181 in determining coverage, reimbursement, or incentive programs under title XVIII in a manner that treats extending the life of an elderly, disabled, or terminally ill individual as of lower value than extending the life of an individual who is younger, nondisabled, or not terminally ill. (2) Paragraph (1) shall not be construed as preventing the Secretary from using evidence or findings from such comparative clinical effectiveness research in determining coverage, reimbursement, or incentive programs under title XVIII based upon a comparison of the difference in the effectiveness of alternative treatments in extending an individual's life due to the individual's age, disability, or terminal illness. (d)(1) The Secretary shall not use evidence or findings from comparative clinical effectiveness research conducted under section 1181 in determining coverage, reimbursement, or incentive programs under title XVIII in a manner that precludes, or with the intent to discourage, an individual from choosing a health care treatment based on how the individual values the tradeoff between extending the length of their life and the risk of disability. (2)(A) Paragraph (1) shall not be construed to-- (i) limit the application of differential copayments under title XVIII based on factors such as cost or type of service; or (ii) prevent the Secretary from using evidence or findings from such comparative clinical effectiveness research in determining coverage, reimbursement, or incentive programs under such title based upon a comparison of the difference in the effectiveness of alternative health care treatments in extending an individual's life due to that individual's age, disability, or terminal illness. (3) Nothing in the provisions of, or amendments made by the Patient Protection and Affordable Care Act, shall be construed to limit comparative clinical effectiveness research or any other research, evaluation, or dissemination of information concerning the likelihood that a health care treatment will result in disability. (e) The Patient-Centered Outcomes Research Institute established under section 1181(b)(1) shall not develop or employ a dollars-per-quality adjusted life year (or similar measure that discounts the value of a life because of an individual's disability or treats extending the life of an elderly, disabled, or terminally ill individual as of lower value than extending the life of an individual who is younger, non-disabled, or not terminally ill) as a threshold to establish what type of health care is cost effective or recommended. [The Secretary shall not] A Federal agency (including the CMI (as described in section 1115A)) or State may not utilize such an adjusted life year (or such a similar measure described in the preceding sentence) as a threshold to determine coverage, reimbursement, or incentive programs [under title XVIII.] under any Federal health care program (as defined in section 1128B, except that such term shall include the health program established under chapter 89 of title 5, United States Code). Notwithstanding any other provision of law, a Federal agency (including the CMI) or State may not waive the application of the provisions of this subsection (or the provisions of section 1852(o), section 1860D-12(h), section 1902(a)(88), section 1932(b)(9), or section 2102(e)) under section 1115, section 1115A, or any other demonstration or waiver authority. * * * * * * * * * * * * * * TITLE XVIII--HEALTH INSURANCE FOR THE AGED AND DISABLED * * * * * * * Part C--Medicare+Choice Program * * * * * * * benefits and beneficiary protections Sec. 1852. (a) Basic Benefits.-- (1) Requirement.-- (A) In general.--Except as provided in section 1859(b)(3) for MSA plans and except as provided in paragraph (6) for MA regional plans, each Medicare+Choice plan shall provide to members enrolled under this part, through providers and other persons that meet the applicable requirements of this title and part A of title XI, benefits under the original medicare fee-for-service program option (and, for plan years before 2006, additional benefits required under section 1854(f)(1)(A)). (B) Benefits under the original medicare fee- for-service program option defined.-- (i) In general.--For purposes of this part, the term ``benefits under the original medicare fee-for-service program option'' means, subject to subsection (m), those items and services (other than hospice care or coverage for organ acquisitions for kidney transplants, including as covered under section 1881(d)) for which benefits are available under parts A and B to individuals entitled to benefits under part A and enrolled under part B, with cost-sharing for those services as required under parts A and B or, subject to clause (iii), an actuarially equivalent level of cost- sharing as determined in this part. (ii) Special rule for regional plans.--In the case of an MA regional plan in determining an actuarially equivalent level of cost-sharing with respect to benefits under the original medicare fee-for-service program option, there shall only be taken into account, with respect to the application of section 1858(b)(2), such expenses only with respect to subparagraph (A) of such section. (iii) Limitation on variation of cost sharing for certain benefits.--Subject to clause (v), cost-sharing for services described in clause (iv) shall not exceed the cost-sharing required for those services under parts A and B. (iv) Services described.--The following services are described in this clause: (I) Chemotherapy administration services. (II) Renal dialysis services (as defined in section 1881(b)(14)(B)). (III) Skilled nursing care. (IV) Clinical diagnostic laboratory test administered during any portion of the emergency period defined in paragraph (1)(B) of section 1135(g) beginning on or after the date of the enactment of the Families First Coronavirus Response Act for the detection of SARS-CoV-2 or the diagnosis of the virus that causes COVID- 19 and the administration of such test. (V) Specified COVID-19 testing-related services (as described in section 1833(cc)(1)) for which payment would be payable under a specified outpatient payment provision described in section 1833(cc)(2). (VI) A COVID-19 vaccine and its administration described in section 1861(s)(10)(A). (VII) A drug or biological product that is a selected drug (as referred to in section 1192(c)). (VIII) Such other services that the Secretary determines appropriate (including services that the Secretary determines require a high level of predictability and transparency for beneficiaries). (v) Exception.--In the case of services described in clause (iv), other than subclauses (IV), (V), and (VI) of such clause, for which there is no cost-sharing required under parts A and B, cost-sharing may be required for those services in accordance with clause (i). (vi) Prohibition of application of certain requirements for covid-19 testing.--In the case of a product or service described in subclause (IV) or (V), respectively, of clause (iv) that is administered or furnished during any portion of the emergency period described in such subclause beginning on or after the date of the enactment of this clause, an MA plan may not impose any prior authorization or other utilization management requirements with respect to the coverage of such a product or service under such plan. (2) Satisfaction of requirement.-- (A) In general.--A Medicare+Choice plan (other than an MSA plan) offered by a Medicare+Choice organization satisfies paragraph (1)(A), with respect to benefits for items and services furnished other than through a provider or other person that has a contract with the organization offering the plan, if the plan provides payment in an amount so that-- (i) the sum of such payment amount and any cost sharing provided for under the plan, is equal to at least (ii) the total dollar amount of payment for such items and services as would otherwise be authorized under parts A and B (including any balance billing permitted under such parts). (B) Reference to related provisions.--For provision relating to-- (i) limitations on balance billing against Medicare+Choice organizations for non-contract providers, see sections 1852(k) and 1866(a)(1)(O), and (ii) limiting actuarial value of enrollee liability for covered benefits, see section 1854(e). (C) Election of uniform coverage determination.--In the case of a Medicare+Choice organization that offers a Medicare+Choice plan in an area in which more than one local coverage determination is applied with respect to different parts of the area, the organization may elect to have the local coverage determination for the part of the area that is most beneficial to Medicare+Choice enrollees (as identified by the Secretary) apply with respect to all Medicare+Choice enrollees enrolled in the plan. (3) Supplemental benefits.-- (A) Benefits included subject to secretary's approval.--Subject to subparagraph (D), each Medicare+Choice organization may provide to individuals enrolled under this part, other than under an MSA plan (without affording those individuals an option to decline the coverage), supplemental health care benefits that the Secretary may approve. The Secretary shall approve any such supplemental benefits unless the Secretary determines that including such supplemental benefits would substantially discourage enrollment by Medicare+Choice eligible individuals with the organization. (B) At enrollees' option.-- (i) In general.--Subject to clause (ii), a Medicare+Choice organization may provide to individuals enrolled under this part supplemental health care benefits that the individuals may elect, at their option, to have covered. (ii) Special rule for msa plans.--A Medicare+Choice organization may not provide, under an MSA plan, supplemental health care benefits that cover the deductible described in section 1859(b)(2)(B). In applying the previous sentence, health benefits described in section 1882(u)(2)(B) shall not be treated as covering such deductible. (C) Application to Medicare+Choice private fee-for-servic

Minority Views

H.R. 485, the Protecting Health Care for All Patients Act of 2023, would prohibit the use of the value measurement Quality Adjusted Life Years (QALYs) and similar measures in coverage and payment determinations under all Federal health care programs. Given concerns that the use of the QALY measurement does not assign an equal value to each life for the purposes of determining the relative value of a health care treatment or prescription drug, the use of this measurement, and similar measures, has been prohibited for the purposes of determining coverage, reimbursement, or incentive programs under title XVIII of the Social Security Act.\1\ As a result, the Medicare program does not utilize the QALY measurement under current law. --------------------------------------------------------------------------- \1\42 U.S.C. 1320e-1(e) --------------------------------------------------------------------------- In addition, the Inflation Reduction Act, which was enacted on August 16, 2022 and provides the Secretary of Health and Human Services (HHS) with the authority to negotiate the price for certain prescription drugs under Medicare, requires that for the purposes of negotiation ``the Secretary shall not use evidence from comparative clinical effectiveness research in a manner that treats extending the life of an elderly, disabled, or terminally ill individual as of lower value than extending the life of an individual who is younger, non-disabled, or not terminally ill.''\2\ --------------------------------------------------------------------------- \2\P.L. 117-169. --------------------------------------------------------------------------- The prohibition on the use of the QALY measurement in current law reflects the concern that the measure places a lower value on treatments which extend the lives of people with chronic illnesses and disabilities, and the elderly. However, the legislation, as amended, could incorrectly be construed in such a way to create a chilling effect on Federal health programs' ability to utilize other value measures that are not discriminatory that are intended to evaluate the effectiveness of health care treatments and prescription drugs and lower costs for the Federal government and for the American people. During the markup of H.R. 485, the Committee considered an amendment that would prohibit the use of the QALY measurement, while emphasizing that the Federal government and states can continue to utilize measures that ``values each year of extended life equally, irrespective of whether the individual is elderly, disabled, or terminally ill.'' This amendment would have reiterated that such measures are nondiscriminatory and encouraged federal healthcare programs to utilize nondiscriminatory measures like these for the purposes of determining value under Federal health programs. Unfortunately, this amendment to the underlying bill was not agreed to. It is imperative that the Federal government effectively determine the value of health care treatments and prescription drugs in order to ensure Federal health programs are good stewards of taxpayer dollars and are paying for effective treatments and cures based on demonstrated value. For these reasons, I oppose H.R. 485. Frank Pallone, Jr., Ranking Member. [all]

Source: https://api.congress.gov/v3/committee-report/118/hrpt/65